This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Array Biopharma Regains Rights to Cancer Drug From Novartis

12/03/14 - 04:01 PM EST

The re-acquisition of binimetinib by Array was expected after Novartis announced in April a business swap with GlaxoSmithKline GSK which included the acquisition of Glaxo's cancer drug business.

READ FULL POST

Amgen Wins U.S. Approval for Immunotherapy Against Leukemia

12/03/14 - 01:31 PM EST

Wednesday's approval of Blincyto comes more than five months ahead of the expected May 19, 2015 approval decision date.

READ FULL POST

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement

12/02/14 - 04:34 PM EST

Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.

READ FULL POST

Future of Exelixis Cancer Drug Dims Further With Second Failed Prostate Cancer Study

12/01/14 - 11:37 AM EST

All too often, promising results from phase II studies don't pan out when larger, confirmatory phase III studies are conducted. That's exactly what happened to Exelixis.

READ FULL POST

Galena, Shunned by Wall Street, Forced to Seek Pricey Vulture Financing

11/24/14 - 09:39 AM EST

The scandal-ridden Galena, still under active SEC investigation, was unable to muster sufficient interest from institutional investors.

READ FULL POST

Royalty Pharma's $3.3 Billion Transaction is Bullish for Vertex Pharma

11/19/14 - 01:25 PM EST

The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.

READ FULL POST

NeoStem's Stem Cell Therapy Fails Mid-Stage Heart Attack Study

11/18/14 - 10:16 AM EST

Using stem cells to repair damaged hearts is a great story, but proof remains elusive.

READ FULL POST

Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson

11/13/14 - 04:34 PM EST

J&J is paying $35 million upfront to Geron for rights to the drug.

READ FULL POST

Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting

11/10/14 - 10:40 AM EST

Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'

READ FULL POST

Update: New Patient Receiving BlueBird Gene Therapy Responding More Slowly

11/06/14 - 11:31 AM EST

The new clinical data on Bluebird's gene therapy are contained in a just-released abstract ahead of next month's American Society of Hematology annual meeting.

READ FULL POST

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs